STEAP1

Chr 7

STEAP family member 1

Also known as: PRSS24, STEAP

NCBI Gene: 26872ENSG00000164647UniProt: Q9UHE8

This gene is predominantly expressed in prostate tissue, and is found to be upregulated in multiple cancer cell lines. The gene product is predicted to be a six-transmembrane protein, and was shown to be a cell surface antigen significantly expressed at cell-cell junctions. [provided by RefSeq, Jul 2008]

95
ClinVar variants
13
Pathogenic / LP
0.00
pLI score
1
Active trials
Clinical Summary— STEAP1
⚡
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
13 Pathogenic / Likely Pathogenic· 72 VUS of 95 total submissions
💊
Clinical Trials
1 active or recruiting trial — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

gnomAD
Tolerant — LoF & missense variants common in population
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
1.20LOEUF
pLI 0.000
Z-score 1.03
OE 0.70 (0.43–1.20)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
0.12Z-score
OE missense 0.97 (0.86–1.11)
164 obs / 168.3 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.70 (0.43–1.20)
0≤0.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.97 (0.86–1.11)
0≤0.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.0.84
0≤1.21.6
LoF obs/exp: 10 / 14.2Missense obs/exp: 164 / 168.3Syn Z: 1.00

ClinVar Variant Classifications

95 submitted variants in ClinVar

ClinVar

Classification Summary

Pathogenic12
Likely Pathogenic1
VUS72
Likely Benign6
Benign1
Conflicting3
12
Pathogenic
1
Likely Pathogenic
72
VUS
6
Likely Benign
1
Benign
3
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
12
0
12
Likely Pathogenic
0
0
1
0
1
VUS
0
51
21
0
72
Likely Benign
0
1
5
0
6
Benign
0
0
0
1
1
Conflicting
—3
Total05239195

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

STEAP1 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

OMIM
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
PubMed
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer.
Nolan-Stevaux O et al.·Cancer Discov
2024
Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study.
Kelly WK et al.·Cancer Discov
2024
Targeting the tumour cell surface in advanced prostate cancer.
Boixareu C et al.·Nat Rev Urol
2025Review
Advances in Targeted Therapy for Metastatic Prostate Cancer.
Grewal K et al.·Curr Treat Options Oncol
2025Review
Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapies.
Zaidi S et al.·Proc Natl Acad Sci U S A
2024
Expression and prognostic analyses of the significance of STEAP1 and STEAP2 in lung cancer.
Liu T et al.·World J Surg Oncol
2022
Exploring STEAP1 Expression in Prostate Cancer Cells in Response to Androgen Deprivation and in Small Extracellular Vesicles.
Bizzaro CL et al.·Mol Cancer Res
2025
Six Transmembrane Epithelial Antigen 1 as a Prognostic Biomarker in Carcinomas: A Meta-Analysis.
Zhao S et al.·Front Biosci (Landmark Ed)
2023Meta-analysis
Clinical significance of STEAP1 extracellular vesicles in prostate cancer.
Khanna K et al.·Prostate Cancer Prostatic Dis
2021
STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score.
Gomes IM et al.·Urol Oncol
2014
Top 10 resultsSearch PubMed ↗
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
Europe PMC
Preclinical Assessment of HLA-A*02:01-Restricted PSMA and STEAP1 Epitopes for Peptide-Based Immunotherapy in Prostate Cancer.
Huang Y et al.·Drug Des Devel Ther
2026🔓 Open Access
Characterization of an anti-STEAP1 T-Cell Dependent Bispecific Antibody for the Treatment of Prostate Cancer and Associated Toxicity in Cynomolgus Monkeys.
Tonkin EG et al.·Toxicol Sci
2026
STEAP1-targeted strategies in advanced prostate cancer: a review on therapeutic and diagnostic implications.
Heo JY et al.·Prostate Cancer Prostatic Dis
2025Review
Collagen-binding IL-12-armoured STEAP1 CAR-T cells reduce toxicity and treat prostate cancer in mouse models.
Sasaki K et al.·Nat Biomed Eng
2025Functional
Head-to-head evaluation of DFO and 3,4,3-LI(1,2-HOPO) chelators through site-specific conjugation of Anti-STEAP1 antibody V6-19-D11 for 89Zr-immuno-PET imaging.
Shah SQ et al.·Appl Radiat Isot
2025
Top 5 resultsSearch Europe PMC ↗

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

ClinicalTrials.gov
Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

RECRUITING
NCT06236139Phase PHASE1, PHASE2Fred Hutchinson Cancer CenterStarted 2024-11-26
Anti-STEAP1 CAR T-cellsBiopsyBiospecimen Collection

External Resources

Links to major genomics databases and tools